<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02333370</url>
  </required_header>
  <id_info>
    <org_study_id>CLEE011A2115C</org_study_id>
    <nct_id>NCT02333370</nct_id>
  </id_info>
  <brief_title>A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer</brief_title>
  <official_title>A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the Phase Ib is to:

        1. determine the recommended dose of LEE011 in combination with a standard dose of
           letrozole as well as to provide additional safety and anti-tumor activity data in Asian
           non-Japanese patients

        2. determine the recommended dose of LEE011 in combination with a standard dose of
           letrozole as well as to provide additional safety and activity data in Japanese patients

        3. evaluate the safety and anti-tumor activity of LEE011 at the RP2D established in the
           dose escalation part in combination with a standard dose of letrozole, fulvestrant or
           tamoxifen plus goserelin in Japanese patients.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 4, 2015</start_date>
  <completion_date type="Anticipated">October 5, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase Ib Dose escalation - Frequency of dose limiting toxicities (DLTs)</measure>
    <time_frame>first cycle (28 days)</time_frame>
    <description>DLTs at each dose level associated with administration of LEE011 and letrozole</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase Ib Dose Expansion: Number of participants with adverse events (AEs)</measure>
    <time_frame>18 months</time_frame>
    <description>This will be defined by changes in hematology and chemistry values, vital signs and ECGs, frequency and duration of AEs, lab abnormalities and other safety parameters.
For LEE011 and letrozole or tamoxifen or fulvestrant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase Ib Dose Expansion: Number of participants with serious adverse events (SAEs)</measure>
    <time_frame>18 months</time_frame>
    <description>This will be defined by changes in hematology and chemistry values, vital signs and ECGs, frequency and duration of SAEs, lab abnormalities and other safety parameters.
For LEE011 and letrozole or tamoxifen or fulvestrant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events (AEs) - Phase Ib dose escalation</measure>
    <time_frame>18 months</time_frame>
    <description>This will be defined by changes in hematology and chemistry values, vital signs and ECGs, frequency and duration of AEs, lab abnormalities and other safety parameters.
For LEE011 and letrozole or tamoxifen or fulvestrant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with serious adverse events (SAEs) - Phase Ib dose escalation</measure>
    <time_frame>18 months</time_frame>
    <description>This will be defined by changes in hematology and chemistry values, vital signs and ECGs, frequency and duration of SAEs, lab abnormalities and other safety parameters.
For LEE011 and letrozole or tamoxifen or fulvestrant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) - Phase Ib dose expansion</measure>
    <time_frame>18 months</time_frame>
    <description>Anti-tumor activity for LEE011 and letrozole or tamoxifen or fulvestrant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR) - Phase Ib dose expansion</measure>
    <time_frame>18 months</time_frame>
    <description>Anti-tumor activity for LEE011 and letrozole or tamoxifen or fulvestrant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Plasma pharmacokinetics (PK) parameters of LEE011 (and relevant metabolites) and letrozole - Phase Ib</measure>
    <time_frame>C1D1, C1D2, C1D8, C1D15, C1D21, C1D22, C2D15, C3D15</time_frame>
    <description>As assessed by PK parameters such as Cmax, Tmax, AUC0-24hours, accumulation ratio and Ctrough for LEE011 (and relevant metabolites) and letrozole, tamoxifen and fulvestrant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) as per RECIST v1.1- phase Ib dose expansion</measure>
    <time_frame>18 months</time_frame>
    <description>Anti-tumor activity for LEE011 and letrozole or tamoxifen or fulvestrant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) - Phase Ib dose expansion</measure>
    <time_frame>18 months</time_frame>
    <description>Anti-tumor activity for LEE011 and letrozole or tamoxifen or fulvestrant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) - Phase Ib dose expansion</measure>
    <time_frame>18 months</time_frame>
    <description>Anti-tumor activity for LEE011 and letrozole or tamoxifen or fulvestrant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) - Phase Ib dose expansion</measure>
    <time_frame>18 months</time_frame>
    <description>Anti-tumor activity for LEE011 and letrozole or tamoxifen or fulvestrant</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer</condition>
  <arm_group>
    <arm_group_label>LEE011 +Letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEE011 - 3 weeks on 1 week off Letrozole 2.5mg - Once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LEE011 + Tamoxifen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEE011 - 3 weeks on 1 week off Tamoxifen 20mg - Once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LEE011 + Fulvestrant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEE011 - 3 weeks on 1 week off Fulvestrant 500 mg - Dosed every 28 days (Day 1 for each cycle) with 1 additional dose on Day 15 of Cycle 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEE011</intervention_name>
    <description>LEE011 as 50 mg and 200 mg hard gelatin oral capsules as individual patient supply packaged in bottles. LEE011 will be taken QD - days 1-21 of each 28 days cycle.</description>
    <arm_group_label>LEE011 +Letrozole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>25mg</description>
    <arm_group_label>LEE011 +Letrozole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
    <description>20 mg</description>
    <arm_group_label>LEE011 + Tamoxifen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>500 mg</description>
    <arm_group_label>LEE011 + Fulvestrant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>goserelin</intervention_name>
    <arm_group_label>LEE011 + Tamoxifen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with advanced (locoregionally recurrent or metastatic) breast cancer not
             amenable to curative therapy (surgery and/or radiotherapy).

          -  Patient has a histologically and/or cytologically confirmed diagnosis of estrogen
             receptor positive and/or progesterone receptor positive breast cancer

          -  Patient has HER2-negative breast cancer

          -  Patient has adequate bone marrow and organ function

        Exclusion Criteria:

          -  Patient who received any CDK4/6 inhibitor.

          -  Patient has a known hypersensitivity to any of the excipients of LEE011 or letrozole

          -  Patients with inflammatory breast cancer.

          -  Patient who received any prior systemic anti-cancer therapy (including hormonal
             therapy and chemotherapy) for advanced breast cancer

          -  Patient is currently using other anti-cancer therapy

          -  Patient has had major surgery within 14 days prior to starting study drug or has not
             recovered from major side effects.

          -  Patient who has received radiotherapy ≤ 4 weeks

          -  Patient has a concurrent malignancy or malignancy within 3 years

          -  Patient has metastases to the central nervous system (CNS).

          -  Patient has a known history of HIV infection

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya-city</city>
        <state>Aichi</state>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sapporo-city</city>
        <state>Hokkaido</state>
        <zip>003-0804</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yokohama-city</city>
        <state>Kanagawa</state>
        <zip>241-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka-city</city>
        <state>Osaka</state>
        <zip>540-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Suita-city</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hidaka-city</city>
        <state>Saitama</state>
        <zip>350-1298</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kitaadachi-gun</city>
        <state>Saitama</state>
        <zip>362-0806</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sunto-gun</city>
        <state>Shizuoka</state>
        <zip>411-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8431</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koto-ku</city>
        <state>Tokyo</state>
        <zip>135 8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>142-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Japan</country>
    <country>Singapore</country>
  </location_countries>
  <removed_countries>
    <country>India</country>
  </removed_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2015</study_first_submitted>
  <study_first_submitted_qc>January 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2015</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced breast cancer</keyword>
  <keyword>Hormone receptor positive</keyword>
  <keyword>HER2-negative</keyword>
  <keyword>LEE011,</keyword>
  <keyword>Letrozole</keyword>
  <keyword>Tamoxifen</keyword>
  <keyword>Fulvestrant</keyword>
  <keyword>Postmenopausal Asian women</keyword>
  <keyword>Pre and Postmenopausal Japanese women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Goserelin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

